TY - JOUR T1 - Sarcoidosis in a time of pandemic JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02376-2020 VL - 56 IS - 3 SP - 2002376 AU - Praveen Govender AU - Yvette C. Cozier Y1 - 2020/09/01 UR - http://erj.ersjournals.com/content/56/3/2002376.abstract N2 - We are living in a historic event: a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China at the end of 2019 and began its global circulation. By January 24, 2020, at least 830 cases and 26 fatalities were reported across Asia and the USA [1]. 6 months later, there are more than 8 million confirmed cases of the disease associated with SARS-CoV-2, coronavirus disease 2019 (COVID-19), and over 430 000 reported deaths worldwide [2]. The pandemic has exposed cracks in healthcare systems throughout the world and identified populations vulnerable for severe disease and poorer outcomes, including the elderly, “essential workers” of lower socioeconomic class, and residents of nursing homes [3]. The Centers for Disease Control (CDC) also state that those with chronic lung disease, namely asthma and COPD, the obese, and those with “prolonged use of corticosteroids and other immune weakening medications” might be at increased risk for COVID-19 related illness [3].Sarcoidosis patients treated with immunosuppressants have a higher risk of serious, recurrent infection. The high morbidity and mortality associated with COVID-19 require a cautious re-evaluation of short- and long-term sarcoidosis treatments. https://bit.ly/2YwZ9wbWe are grateful to Jeffrey Berman for his editorial feedback and mentorship. ER -